Portola Pharmaceuticals, Inc. (PTLA) Analysts See $-1.46 EPS

May 9, 2018 - By Richard Conner

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) LogoInvestors sentiment decreased to 1.36 in 2017 Q4. Its down 0.80, from 2.16 in 2017Q3. It dropped, as 32 investors sold Portola Pharmaceuticals, Inc. shares while 45 reduced holdings. 30 funds opened positions while 75 raised stakes. 56.35 million shares or 0.04% more from 56.33 million shares in 2017Q3 were reported.
Hanseatic Inc holds 0.21% or 4,247 shares. Natixis reported 13,164 shares. Bank Of America De, North Carolina-based fund reported 196,150 shares. Dupont Capital Mgmt Corp reported 4,977 shares stake. Stratos Wealth Prtnrs Ltd has 21 shares. Art Advsrs Limited Liability Company has invested 0.03% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Fernwood Inv Mngmt Lc has invested 5.95% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Highland Capital Mngmt Lp has invested 0.99% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Artal Gru invested 0.11% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Aperio Group Inc Limited Co holds 0% or 4,770 shares. American Intll Gp Incorporated reported 0.01% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). New York-based Renaissance Technology Limited Liability Corporation has invested 0.02% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). 684 are held by Bank Of Montreal Can. Hoertkorn Richard Charles holds 0.01% or 500 shares in its portfolio. Moreover, Loring Wolcott And Coolidge Fiduciary Advsr Ltd Liability Partnership Ma has 0% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Since December 15, 2017, it had 0 buys, and 2 selling transactions for $607,613 activity. On Friday, December 15 the insider Wolff Henry Ward sold $563,950.

Analysts expect Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report $-1.46 EPS on May, 14.They anticipate $0.72 EPS change or 97.30 % from last quarter’s $-0.74 EPS. After having $-1.41 EPS previously, Portola Pharmaceuticals, Inc.’s analysts see 3.55 % EPS growth. The stock decreased 0.19% or $0.08 during the last trading session, reaching $42.28. About 1.84M shares traded or 21.64% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 20.86% since May 10, 2017 and is downtrending. It has underperformed by 32.41% the S&P500.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharma (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharma had 13 analyst reports since December 1, 2017 according to SRatingsIntel. Goldman Sachs initiated Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Friday, December 1 with “Buy” rating. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Equal-Weight” rating by Morgan Stanley on Thursday, March 1. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Tuesday, March 13 by Oppenheimer. The rating was maintained by Oppenheimer with “Buy” on Tuesday, December 19. Oppenheimer maintained the shares of PTLA in report on Thursday, December 28 with “Buy” rating. Morgan Stanley maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Thursday, February 22 with “Overweight” rating. On Friday, May 4 the stock rating was maintained by Cowen & Co with “Buy”. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Monday, January 15 with “Buy” rating. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, March 13. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, May 7.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $2.78 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Nasdaq.com which released: “3 Healthcare Stocks That Soared This Week: Are They Buys?” on May 05, 2018, also Bizjournals.com with their article: “As emergency blood-thinner antidote scores FDA OK, Peninsula drug maker’s stock soars” published on May 04, 2018, Streetinsider.com published: “Pre-Open Stock Movers 05/04: (PTLA) (CVGI) (SHAK) Higher; (IMTE) (FLR) (ANET) Lower (more…)” on May 04, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Seekingalpha.com and their article: “Reader Inquiry: After Approval Is Portola Pharmaceuticals A Buy?” published on May 08, 2018 as well as Nasdaq.com‘s news article titled: “This Biotech Stock Could Be Like Buying Celgene in 2006” with publication date: May 05, 2018.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: